USP30-IN-20

USP30-IN-20 is an orally active USP30 inhibitor with a Kd of 1.61 μM and an IC50 of 12.8 μM. It induces ferroptosis by promoting the ubiquitination-mediated degradation of GPX4. This compound inhibits the proliferation, migration, and invasion of prostate cancer cells and induces G0/G1 phase arrest while increasing ROS levels. In a mouse xenograft model with PC3 cells, USP30-IN-20 demonstrates significant antitumor activity. It is applicable for advanced prostate cancer research.